Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Paclitaxel Plus Systemic Chemotherapy Versus Systemic Chemotherapy Alone for Advanced or Recurrent Gastric and Gastro-oesophageal Junction Adenocarcinoma with Peritoneal Metastasis (PIPS-GC 003)
KCT0009110Phase 3Not yet recruiting
- Sponsor
- Chong Kun Dang
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paclitaxel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, peritoneal carcinomatosis (PC), sponsored by Chong Kun Dang. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on KCT0009110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009110.